Pasithea Therapeutics Corp KTTA

Healthcare Biotechnology

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

NDAQ:KTTA - Post by User

Pasithea Therapeutics Corp

<< Previous

Bullboard Posts

Next >>

Post by Iseneschalon Nov 23, 2021 3:37pm

85 Views

Post# 34158561

KTTA ..... Looking back on todays trading

KTTA's performance really stands out....Volume & price action

It's only up over 200%....and it stay that way

Not too shaby

Gonna keep this on watch

Just sayin

Cheers !

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023